UPDATE: Unfortunately the Betatrophin paper discussed here originally back in 2013 has now largely been proven to have come to incorrect conclusions (for more read this). Today Harvard Stem Cell Institute (HSCI) reported the discovery, in a paper in Cell by Harvard Professor Doug Melton, of a powerful new hormone called Betatrophin that can stimulate …
Sometimes a post here on The Niche (named after the stem cell niche) sparks a debate between expert stem cell researchers and often that gives much more depth to a topic. Such was the case with my post this week on where things stand with stem cell therapy for heart disease. It led to a …
Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more Read More »
It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on …
ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »
Many of us first became aware of Vivek Ramaswamy as a Republican candidate for President. He was most well-known prior to that as a biotech leader. Given that biotech background, I decided to learn more about him. Surprisingly, his biomedical efforts may have started with stem cells. That caught my attention. This was way back during …
Vivek Ramaswamy & his surprising stem cell start Read More »
The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative …
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are …
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
I remember the first time I ever witnessed human cell division first hand and it was really excitement. I was working as a part-time tech in the Lane Lab at UC San Diego School of Medicine. We studied heart disease and grew human umbilical cord endothelial cell cultures. It was striking to see a plate …
Weekly reads: Vertex hold, new type of cell division in fish, CAR-T Read More »
It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This …
Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »
ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …
ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »
What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …
ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »